FDA Approves Pembrolizumab for Locally Advanced Cutaneous Squamous Cell Carcinoma

The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that was not curable by surgery or radiation.